

Drug and Therapeutics Committee – Minutes

Date / Time	8 th June 2023
Venue	MS Teams
Chair	Prof A Morice, Chair, Professor of Respiratory Medicine
Notes / Action Points	Luke Storr – Senior Pharmacy Technician, Formulary HUTH
Quorate: Yes / No	Yes

Prof A Morice, Chair, Professor of Respiratory Medicine
Miss J Morgan, Professional Secretary, Principal Pharmacist – Formulary HUTH
Luke Storr – Senior Pharmacy Technician, Formulary HUTH
Mr K McCorry, Medicines Optimisation Pharmacist, NECS
Dr O Ogunbambi, Consultant Rheumatologist, HUTH
Dr S Raise, GP Prescribing Lead, East Riding
Dr A Samson, Consultant Infectious Diseases, HUTH
Dr H Klonin, Consultant Paediatrician, HUTH
Dr A Ramirez, Deputy Chief Pharmacist, HUTH

Apologies

Ms J Goode, Chief Pharmacist, HUTH
Prof M Lind, Vice Chair, Professor of Oncology, HUTH

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
		<p>New action: Add guidance to agenda when updated Update February 2023 on agenda</p> <p>New action Sept 2022: Present audit of ustekinumab Update April 2023: JM to discuss with Sarah Westerhold (SHG lead pharmacist). Update May 2023: JM and Sarah Westerhold had reviewed data, which showed compliance with commissioning. Audit report to be submitted to D&TC when complete</p> <p>Terms of reference update JM to contact Andy Lockwood regarding patient representation on D&TC December update: - JM to chase Andy Lockwood as no response received Update February 2023 – JM has been in touch with Andy Lockwood, original email missed, he will get back to us once he has found someone willing to join. Await response Update June 2023 – JM to present at PE&CE</p> <p>New Product Requests JM to add aprotinin audit to agenda in 6 months time</p> <p>New Product Requests AM to write to applicants</p> <p>New Product Requests LS to update formulary</p> <p>New Product Requests AM to write to Prof Sathyapalan to discuss Hydrocortisone MR</p> <p>NICE guidance LS to update back of formulary</p> <p>Clinical Guidelines JM to discuss dissemination of electrolyte guidance with Jane Conway</p> <p>Any other business</p>	Complete		JM		
			Awaiting Audit report		JM		
			Ongoing	Sent to PE+CE	JM	7/23	
					JM	12/23	
					AM	6/23	
					LS	6/23	
					AM	6/23	
					LS	6/23	
			Complete		JM	6/23	

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
		To review rheumatology pathways and submit for approval			OO	9/23	
23.06.05	New Product Requests	<p><i>New Product Requests</i> a) Teduglutide- Dr Smithson- TA804 Approved in line with NICE, NHSE commissioned.</p> <p>b) IV ibuprofen- Claire Eastwood Discussed differences in prices from application to pharmacy prices. JM to check pricing with Claire Eastwood. Approved in paediatrics; parecoxib is not licensed in children.</p> <p>c) Tenecteplase(Acute stroke)- Dr Esisi Previously received application for use of tenecteplase in a subset of patient. Safety concerns were raised on the initial application and the team have considered and national (Royal College) guidance has now been updated to recommend either alteplase or tenecteplase for acute stroke. Approved use for tenecteplase to be used for stroke thrombolysis (when stock available).</p> <p><i>ARIA FORMs</i> d) Daralutamide and docetaxel- Dr Dixit (CDF- DARO2 v1.0) – Approved in line with CDF</p> <p><i>DIETETIC REQUESTS</i> e) Fortisip 2kcal Nutricia are reviewing the products they make are rationalising products to improve supply. JM to check formulary against currently available fortisip lines and contact applicant.</p>	<p>a) Approved b) Approved in Paeds not in Adults c) Approved- no stock till 01/24 d) Approved e) Approved</p>	AM to write applicants LS to update formulary			
23.06.06	Supply issues	Nil this month					
23.06.07	NICE guidance	<p>May 2023</p> <ul style="list-style-type: none"> TA881 Ripretinib for treating advanced gastrointestinal stromal tumour after 3 or more treatments 	Not recommended				

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
		<ul style="list-style-type: none"> • TA882 Voclosporin with mycophenolate mofetil for treating lupus nephritis • TA883 Tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma • TA884 Capmatinib for treating advanced non-small-cell lung cancer with MET exon 14 skipping (terminated appraisal) • TA885 Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer • TA886 Olaparib for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy • TA887 Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer • NG18 Diabetes (type 1 and type 2) in children and young people: diagnosis and management Updated, no formulary updates needed • NG198 Acne vulgaris: management • TA888 Risankizumab for previously treated moderately to severely active Crohn's disease Confirmed with Prof Sebastian that would like access to. • TA889 Ciltacabtagene autoleucel for treating relapsed or refractory multiple myeloma (terminated appraisal) • TA890 Difelikefalin for treating pruritus in people having haemodialysis • NG232 Head injury: assessment and early management • CG181 Cardiovascular disease: risk assessment and reduction, including lipid modification • TA892 Mosunetuzumab for treating relapsed or refractory follicular lymphoma • TA891 Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemia 	<p>Not on formulary Not recommend</p> <p>Terminated appraisal</p> <p>On formulary</p> <p>On formulary</p> <p>On formulary</p> <p>Noted</p> <p>Noted On formulary – update into gastro section</p> <p>Terminated appraisal</p> <p>Not on formulary</p> <p>Updated</p> <p>Nil for D&TC</p> <p>Not recommended</p> <p>On formulary</p>				
23.06.08	MHRA Drug safety	<ul style="list-style-type: none"> • May 2023 					

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
	update –						
23.06.09	Minutes of the Safe Medication Practice Committee –	<ul style="list-style-type: none"> March 2023 	Noted				
23.06.10	Minutes from the Humber Area Prescribing Committee –	Nil this month					
23.06.11	Regional Medicines Optimisation Committee	Nil this month					
23.06.12	Clinical guidelines	Nil this month					
23.06.13	Correspondence received	Nil this month					
23.06.14	Chairs approvals						
23.06.15	Issues to escalate to Patient Safety and Clinical Effectiveness	JM to raise Hydroxychloroquine issue					
23.06.16	Any other business	JM raised ophthalmology non-formulary items are being used within ophthalmology and within outpatients		JM/LS to review items used			
	Date and time of next meeting	13 th July Thursday 8.15am 2023 Microsoft Teams / Alderson House HRI					